160 related articles for article (PubMed ID: 35868619)
1. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases.
Zhang G; Li B; Yin X; Gao S; Shen S; Wang H; Shi X; Liu W; Zheng K; Jing W; Zhang Y; He T; Li G; Hu X; Guo S; Jin G
Int J Surg; 2022 Aug; 104():106786. PubMed ID: 35868619
[TBL] [Abstract][Full Text] [Related]
2. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients.
Shin SH; Kim SC; Song KB; Hwang DW; Lee JH; Park KM; Lee YJ
Surgery; 2018 Sep; 164(3):432-442. PubMed ID: 29884479
[TBL] [Abstract][Full Text] [Related]
3. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
4. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.
Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y
BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066
[TBL] [Abstract][Full Text] [Related]
5. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
6. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
7. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: Long-term oncologic outcomes after standard resection.
Sahakyan MA; Kim SC; Kleive D; Kazaryan AM; Song KB; Ignjatovic D; Buanes T; Røsok BI; Labori KJ; Edwin B
Surgery; 2017 Oct; 162(4):802-811. PubMed ID: 28756944
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.
Maire F; Hammel P; Terris B; Paye F; Scoazec JY; Cellier C; Barthet M; O'Toole D; Rufat P; Partensky C; Cuillerier E; Lévy P; Belghiti J; Ruszniewski P
Gut; 2002 Nov; 51(5):717-22. PubMed ID: 12377813
[TBL] [Abstract][Full Text] [Related]
10. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
[No Abstract] [Full Text] [Related]
12. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
[TBL] [Abstract][Full Text] [Related]
15. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma.
Lewis R; Drebin JA; Callery MP; Fraker D; Kent TS; Gates J; Vollmer CM
HPB (Oxford); 2013 Jan; 15(1):49-60. PubMed ID: 23216779
[TBL] [Abstract][Full Text] [Related]
16. Vascular resection for locally advanced pancreatic ductal adenocarcinoma: analysis of long-term outcomes from a single-centre series.
Feo CF; Deiana G; Ninniri C; Cherchi G; Crivelli P; Fancellu A; Ginesu GC; Porcu A
World J Surg Oncol; 2021 Apr; 19(1):126. PubMed ID: 33866970
[TBL] [Abstract][Full Text] [Related]
17. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
18. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival after pancreaticoduodenectomy in patients with ductal adenocarcinoma of the pancreatic head.
Luu AM; Braumann C; Belyaev O; Janot-Matuschek M; Rudolf H; Praktiknjo M; Uhl W
Hepatobiliary Pancreat Dis Int; 2021 Jun; 20(3):271-278. PubMed ID: 33349608
[TBL] [Abstract][Full Text] [Related]
20. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.
Groot VP; Gemenetzis G; Blair AB; Rivero-Soto RJ; Yu J; Javed AA; Burkhart RA; Rinkes IHMB; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
Ann Surg; 2019 Jun; 269(6):1154-1162. PubMed ID: 31082915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
